Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million
Published on
Paris, February 13th, 2012 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, is announcing the redemption of all the bonds redeemable into shares (ORA) issued on November 3rd, 2011 to the FSI and Pierre Bastid for a total amount of €50 million and the corresponding interest.
Paris, February 13th, 2012 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, is announcing the redemption of all the bonds redeemable into shares (ORA) issued on November 3rd, 2011 to the FSI and Pierre Bastid for a total amount of €50 million and the corresponding interest.
Under the terms of the bonds redeemable into shares, the Board of directors has acknowledged their automatic early redemption into a total of 6,250,000 Company shares, at a price of €8 per share of a nominal value of €0.05, or an issue premium of €7.95 per share. This redemption follows the average closing share price (volume-weighted) exceeding €8 for three consecutive trading days. The volume-weighted average closing price recorded for the Company's shares between February 1st and 3rd, 2012 was €8.06.
The Board of Directors, acting upon the delegation given by the general shareholders meeting of October 28th, 2011, has decided to issue to the FSI and Pierre Bastid, on an equal basis, a total of 54,660 additional new shares with a nominal value of €0.05 per share at a price of €7.8392, giving a premium of €7.7892 per share. This operation represents a subscription of a total of €428,490.672 euros (including issue premium). By offsetting the debt, it will make it possible to clear the interest owed by the Company to the FSI and Pierre Bastid in relation to the bonds redeemable into shares.
Following this principal and interest-based redemption, the total number of outstanding shares is 20,434,714. The FSI and Pierre Bastid each hold 3,152,330 shares, representing approximately 15.4% of Cellectis capital.